Literature DB >> 36159217

Peritoneal metastases of unknown primary with hepatoid features.

Lakhdar Khellaf1, Stéphanie Nougaret2, Sébastien Carrère3, Frédéric Bibeau4.   

Abstract

Entities:  

Keywords:  ectopic liver; hepatocellular carcinoma; hepatoid adenocarcinoma; sal-like protein 4

Year:  2022        PMID: 36159217      PMCID: PMC9467897          DOI: 10.1515/pp-2022-0113

Source DB:  PubMed          Journal:  Pleura Peritoneum        ISSN: 2364-768X


× No keyword cloud information.
A 59-year-old woman presented with isolated peritoneal metastases in the context of elevated serum AFP levels (Figure 1A and B). No primary tumour was found, notably from the liver, the gastrointestinal or gynecological tracts. A laparoscopic assessment reported a peritoneal cancer index (PCI) reaching 22/39 and biopsies performed disclosed hepatocellular carcinoma (HCC). A chemotherapy followed by a cytoreductive surgery/hyperthermic intraoperative intra-peritoneal chemotherapy (HIPEC) was given, leading to a complete macroscopic clearance. Ultimately, liver metastases appeared, resulting in death.
Figure 1:

Magnetic resonance imaging (MRI) of the liver and peritoneum (axial T2 weighted images).

(A) Initial MRI: ill-defined T2 hyperintense nodule within the falciform ligament of the liver (arrow). (B) MRI at 3 months: Appearance of several peritoneal metastases (arrows). Note the absence of any parenchymal liver tumour in both images. (C) Histopathological analysis: hepatocellular carcinoma (asterisks) in the falciform ligament of the liver, representing the starting point of the peritoneal disease. Ectopic liver is circled in red (greater axis: 15 mm), with detectable steatosis (HES, ×6). Note the independent vasculo-biliary stalk, highlighted in the inset (HES, ×50). HES: hematoxylin-eosin-saffron.

Magnetic resonance imaging (MRI) of the liver and peritoneum (axial T2 weighted images). (A) Initial MRI: ill-defined T2 hyperintense nodule within the falciform ligament of the liver (arrow). (B) MRI at 3 months: Appearance of several peritoneal metastases (arrows). Note the absence of any parenchymal liver tumour in both images. (C) Histopathological analysis: hepatocellular carcinoma (asterisks) in the falciform ligament of the liver, representing the starting point of the peritoneal disease. Ectopic liver is circled in red (greater axis: 15 mm), with detectable steatosis (HES, ×6). Note the independent vasculo-biliary stalk, highlighted in the inset (HES, ×50). HES: hematoxylin-eosin-saffron. All surgical specimens histologically showed features of HCC. An unsuspected ectopic liver (EL) was observed within the falciform ligament of the liver, in close vicinity of tumour (Figure 1C), strongly suggesting an EL cancerization [1, 2]. This unusual clinical presentation may first suggest a peritoneal extension from a liver HCC, which is usually encountered in massive-type tumours [3]. Rare hepatoid carcinomas can also be suspected in the context of a primary gastric tumour showing an adenocarcinomatous component with positive Sal-like protein 4 (SALL4) immunostaining [4].
  4 in total

1.  Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature.

Authors:  M Arakawa; Y Kimura; K Sakata; Y Kubo; T Fukushima; K Okuda
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

2.  Hepatocellular carcinoma arising in the abdominal cavity. An autopsy case of ectopic liver origin.

Authors:  E Kawahara; T Kitamura; H Ueda; T Ogino; M Mai; A Ooi; I Nakanishi
Journal:  Acta Pathol Jpn       Date:  1988-12

3.  SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.

Authors:  Tetsuo Ushiku; Aya Shinozaki; Junji Shibahara; Yoshiaki Iwasaki; Yoko Tateishi; Nobuaki Funata; Masashi Fukayama
Journal:  Am J Surg Pathol       Date:  2010-04       Impact factor: 6.394

4.  Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases.

Authors:  K Yuki; S Hirohashi; M Sakamoto; T Kanai; Y Shimosato
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.